Business
SEED Therapeutics Completes $30 Million Series A-3 Financing
KING OF PRUSSIA, Pa., Sept. 23, 2025 (GLOBE NEWSWIRE) -- SEED Therapeutics, Inc. (“SEED”), a clinical-stage biotechnology company pioneering rational molecular glue degraders for historically undruggable disease drivers, today announced the successful completion of its $30 million Series A-3 financing, alongside U.S. Food and Drug Administration (FDA) clearance of its Investigational New Drug (IND) application for its lead program targeting RBM39. The company anticipates entering first-in-human
About this update from Eisai Co., Ltd.
[{"type":"image","alt":"SEED Therapeutics","displaySize":"","headline":null,"caption":"SEED Therapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":182,"url":"https://media.zenfs.com/en/globenewswire.com/b1a0bc30f47159309d845bde77680c96"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/TqB7TU.EjFGCCloWcOiMIQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTI1NTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/b1a0bc30f47159309d845bde77680c96","width":300,"height":182}},"lazy":false},{"type":"text","content":"KING OF PRUSSIA, Pa., Sept. 23, 2025 (GLOBE NEWSWIRE) -- SEED Therapeutics, Inc. (“SEED”), a clinical-stage biotechnology company pioneering rational molecular glue degraders for historically undruggable disease drivers, today announced the successful completion of its $30 million Series A-3 financing, alongside U.S. Food and Drug Administration (FDA) clearance of its Investigational New Drug (IND) application for its lead program targeting RBM39. The company anticipates entering first-in-human clinical trials of ST-01156 in Q1 2026.","length":554,"tagName":"p"},{"type":"text","content":"The $30 million Series A-3 financing consists of a $24 million first close completed in August 2024 and a $6 million second close completed in August 2025. In addition, SEED has received close to $60 million in equity, as well as collaboration upfront and milestone payments combined, from its partnerships with Eli Lilly and Eisai reflecting strong partner validation of its scientific platform.","length":416,"tagName":"p"},{"type":"text","content":"Lan Huang, Ph.D., SEED Co-Founder, Chairman, and Chief Executive Officer, said:“FDA clearance of our IND is a defining milestone for SEED, marking our transition into a clinical-stage company. ST-01156 represents the first of a new generation of rationally designed molecular glue degraders. We continue to translate innovation into meaningful therapies for patients.”","length":369,"tagName":"p"},{"type":"text","content":"Bill Desmarais, SEED Chief Financial Officer and Chief Business Officer, added:“Our equity financing, together with collaboration payments from Eli Lilly and Eisai, supplement our resources to move confidently into the clinic and to continue building a broad pipeline. We have the partners, capital, and momentum to deliver on SEED’s stra...